

6th

International Conference on

Thrombosis and Hemostasis Issues in Cancer

Bergamo, Italy April 20-22, 2012

6th ICTHIC Preliminary Scientific Program**Friday, April 20th, 2012**

2.00 - 2.15 pm Opening: A. Falanga, F.R. Rickles, B. Brenner

2.15 - 4.30 pm **Plenary Session 1: Epidemiology and risk factors of venous thromboembolism**

Chairs: H.A. Liebman (USA), I. Pabinger (Austria)

- Predictive potential of hemostatic biomarkers

C. Ay (*Austria*)

- Update on thrombotic risk stratification

A. Khorana (*USA*)

- Unsuspected PE in cancer patients

M. Monreal (*Spain*)

- Cancer in pregnancy

B. Brenner (*Israel*)

Oral Communications (from abstracts)

5.00 - 7.15 pm **Plenary Session 2: Genomics and proteomics of the hemostatic system in cancer**

Chairs: M.-M. Samama (France), M. Cattaneo (Italy)

- Genetic pathways linking hemostasis and cancer

J. Rak (*Canada*)

- Platelet CLEC-2 in lymphangiogenesis and cancer metastasis

S.P. Watson (*UK*)

- The platelet proteome

W.F. Bahou (*USA*)

- Akt and Ras pathways and modulation of TF expression in glioblastoma

D. Brat (*USA*)

Oral Communications (from abstracts)

7.30 pm **Plenary Lecture: 2nd Simon Karparkin Memorial Lecture**

Introduction F.R. Rickles (USA)

- Hemostasis, innate immunity and malignancy

J.L. Degen (*USA*)

Saturday, April 21st, 2012

8.15 - 10.30 am **Plenary Session 3 : Bleeding complications in cancer patients**

Chairs: C.M. Kessler (USA), C. Velati (Italy)

- Side effects of anti-angiogenic drugs

F. Rodeghiero (*Italy*)

- Diagnosis and treatment of disseminated intravascular coagulation

C.-H. Toh (*UK*)

- Transfusion issues in the cancer patient

A.B. Federici (*Italy*)

- Acquired hemophilias in cancer

N.S. Key (*USA*)

Oral Communications (from abstracts)

11.00 am - 1.15 pm **Plenary Session 4: Coagulation and cancer progression**

Chairs: M.B. Donati (Italy), R. Labianca (Italy)

- The respective roles of TF isoforms in cancer

H.H. Versteeg (*Netherlands*)

- Heparanase procoagulant activity

Y. Nadir (*Israel*)

- Protein C and cancer

C.A. Spek (*Netherlands*)

- Accounting for death as a competing risk in cancer VTE studies

J.I. Zwicker (*USA*)

6th

International Conference on

Thrombosis and Hemostasis Issues in Cancer

Bergamo, Italy April 20-22, 2012



Oral Communications (from abstracts)

2.15 - 4.30 pm **Plenary Session 5: Hematological disorders**

Chairs: G.H. Lyman (USA), T. Barbui (Italy)

- Risk and management of thrombosis in multiple myeloma
F.W. Leebeek (*Netherlands*)
 - The role of JAK-2 inhibition
A. Rambaldi (*Italy*)
 - Splanchnic vein thrombosis: New risk factors and management
W. Ageno (*Italy*)
 - Heparin-induced thrombocytopenia in cancer
P.M. Sandset (*Norway*)
- Oral Communications (from abstracts)

5.00 - 7.15 pm **Plenary Session 6: Anticoagulants and cancer**

Chairs: S. Schulman (Canada), H.R. Büller (Netherlands)

- New and old anticoagulants in cancer
G. Agnelli (*Italy*)
 - Guidelines for antithrombotics in cancer patients
D. Farge-Bancel (*France*)
 - Measurement of new oral anticoagulants
J. Harenberg (*Germany*)
 - LMWH and survival in lung cancer
S. Noble (*UK*)
- Oral Communications (from abstracts)

Sunday, April 22nd, 2012

8.15 - 10.30 am **Plenary Session 7: Platelets and vascular endothelium**

Chairs: C.W. Francis (USA), H. ten Cate (Netherlands)

- The role of thrombomodulin in tumor growth and metastasis
N. Horowitz (*Israel*)
 - Endothelial cell activation markers in cancer
A.D. Blann (*UK*)
 - Novel functions of tissue factor in thrombosis and in cancer
W. Ruf (*USA*)
 - Microparticles and angiogenesis
A. Falanga (*Italy*)
- Oral Communications (from abstracts)

11.00 am - 1.15 pm **Plenary Session 8: Prevention and treatment of thrombosis**

Chairs: M.N. Levine (Canada), P. Prandoni (Italy)

- Thromboprophylaxis in the cancer surgical patient
A.K. Kakkar (*UK*)
 - Thromboprophylaxis in the cancer medical patient
A.T. Cohen (*UK*)
 - Treatment of established thrombotic events
A.Y. Lee (*Canada*)
 - Overview of thrombosis and cancer survival
N. Kuderer (*USA*)
- Oral Communications (from abstracts)

2.30 - 4.30 pm **Poster Sessions**